81 – 90 of 533
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
The need for core outcome sets in renal cancer clinical effectiveness research
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Salvage radiotherapy after radical prostatectomy : functional outcomes in the LAPPRO trial after 8-year follow-up
(
- Contribution to journal › Article
-
Mark
Urodrill - a novel MRI-guided endoscopic biopsy technique to sample and molecularly classify muscle-invasive bladder cancer without fractionating the specimen during transurethral resection
(
- Contribution to journal › Article
-
Mark
Urosymphyseal fistula after pelvic radiotherapy in a tertial referral centre - a rare entity with significant comorbidity requiring multidisciplinary management
(
- Contribution to journal › Article
-
Mark
Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14)
(
- Contribution to journal › Article
-
Mark
Re : Niraparib and Abiraterone Acetate for Metastatic Castration-resistant Prostate Cancer
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Local Treatment of Recurrent Renal Cell Carcinoma May Have a Significant Survival Effect Across All Risk-of-recurrence Groups
(
- Contribution to journal › Article
- 2022
-
Mark
Risk of hernia formation after radical prostatectomy : a comparison between open and robot-assisted laparoscopic radical prostatectomy within the prospectively controlled LAPPRO trial
(
- Contribution to journal › Article
-
Mark
Reply to Wei Zhang So, Ziting Wang, and Ho Yee Tiong's Letter to the Editor re : Anna Lantz, David Bock, Olof Akre, et al. Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up. Eur Urol 2021;80:650–60
(
- Contribution to journal › Letter
-
Mark
Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316-7. Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?
(
- Contribution to journal › Letter